7 Results for "

EGFR-expressing cells

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "EGFR-expressing cells" in MCE Product Catalog:

Cat. No.: HY-171135
Research Areas:  

Cancer

Cetuximab MMAE is an antibody-drug conjugate (ADC) targeting EGFR, formed by the random conjugation of the Cetuximab (HY-P9905) antibody and VcMMAE (HY-15575) via reduced interchain cysteines. Cetuximab MMAE binds to EGFR, blocks ligand interactions, inhibits downstream signal transduction, mediates receptor internalization, and delivers MMAE to induce G2/M phase cell cycle arrest, inhibit microtubule polymerization, interfere with mitosis, and exert radiosensitizing effects. Cetuximab MMAE limits the toxicity of free MMAE to EGFR-expressing cells and circumvents EGFR resistance mechanisms. Cetuximab MMAE is applicable to research related to EGFR + tumors .
loading...
    loading...
Cat. No.: HY-P9964
CAS No.: 906805-06-9
Synonyms: 11F8; IMC-11F8; LY3012211

Target:  

EGFR

Research Areas:  

Cancer

Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
loading...
    loading...
Cat. No.: HY-172470
Target:  

Liposome EGFR

Research Areas:  

Cancer

DSPE-PEG2000-GE11 is a nanocarrier component composed of DSPE and the EGFR-targeting peptide (GE11). DSPE-PEG2000-GE11 specifically binds to EGFR and mediates receptor-mediated endocytosis of micellar drug carriers. DSPE-PEG2000-GE11 can be used for drug delivery .
loading...
    loading...
Cat. No.: HY-D2170
AF488 streptavidin is a fluorescently labeled streptavidin. AF488 streptavidin is a streptavidin conjugated to Alexa Fluor 488, with 4 fluorophores per protein molecule, enabling stoichiometric fluorescent labeling of cell surface targets. AF488 streptavidin can form a complex with biotinylated E07 aptamer to stain cells expressing EGFR, and the staining is reversible after treatment with mA9 detoxifying oligonucleotides (Ex/Em = 470/520 nm) .
loading...
    loading...
Cat. No.: HY-112806
CAS No.: 2247025-63-2
ST8155AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor. ST8155AA1 induces α-tubulin, histone H3/H4 acetylation via direct enzymatic inhibition. ST8155AA1 recognizes and binds EGFR, undergoes internalization into EGFR-expressing tumor cells. ST8155AA1 inhibits cancer cell proliferation and exerts activity in mouse tumor models. ST8155AA1 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P99295A
Synonyms: RG 7160 (FUT8-KO); RO 5083945 (FUT8-KO); Anti-EGFR Recombinant Antibody (FUT8-KO)

Target:  

EGFR

Research Areas:  

Cancer

Imgatuzumab (FUT8-KO) is a humanized monoclonal antibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.
loading...
    loading...
Cat. No.: HY-171884
CAS No.: 2769714-36-3
Target:  

EGFR

Research Areas:  

Cancer

BI-8128 is a potent EGFR inhibitor, with IC50 values of 12, 6.7, 22, 10, and 3 nM against wild-type, T790M, C797S, T790M/C797S, and L858R/T790M/C797S mutant EGFR, respectively. BI-8128 significantly inhibits the proliferation of Ba/F3 and PC-9 drug-resistant mutant cells. BI-8128 is applicable for the research of non-small cell lung cancer .
loading...
    loading...